I can't Cuppa. Two things are clear to me. Firstly, they did the best (and likely only) deal that they could. Secondly, there has been tremendous over-estimation of the current perceived strength of their IP, both by speculative investors and management themselves. Overseas institutions are not going to pile in - yet.
That may begin to manifest itself in time, but will require news of progress - toxicity studies; manufacturing situation; pathway to Rett's P3 iniation; Fragile X plans and implementation; N2591 studies.
All of these aspects will (hopefully) filter through with time, but until news begins to flow the SP will be left to stagnate or drift.
[Perhaps something is in the short term pipeline due to the deferrment of Lanstead payments. However I am a bit skeptical on that front.]
This is now a much longer term play than was envisaged six months ago. But after all, it is Biotech, so everyone who is staying had better adjust. $3 is many, many moons into the future.
NEU Price at posting:
$1.14 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)